Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Update on herpes zoster vaccination: a family practitioner's guide.

Shapiro M, Kvern B, Watson P, Guenther L, McElhaney J, McGeer A.

Can Fam Physician. 2011 Oct;57(10):1127-31. Review.

2.

Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2008 Jun 6;57(RR-5):1-30; quiz CE2-4.

3.

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Pellissier JM, Brisson M, Levin MJ.

Vaccine. 2007 Nov 28;25(49):8326-37. Epub 2007 Oct 17.

PMID:
17980938
4.

Vaccination against herpes zoster in developed countries: state of the evidence.

Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M.

Hum Vaccin Immunother. 2013 May;9(5):1177-84. doi: 10.4161/hv.23491. Epub 2013 Jan 16. Review.

5.

Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.

Tseng HF, Lewin B, Hales CM, Sy LS, Harpaz R, Bialek S, Luo Y, Jacobsen SJ, Reddy K, Huang PY, Zhang J, Anand S, Bauer EM, Chang J, Tartof SY.

J Infect Dis. 2015 Oct 15;212(8):1222-31. doi: 10.1093/infdis/jiv244. Epub 2015 Jun 1.

6.

The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.

Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.

Hum Vaccin. 2008 May-Jun;4(3):238-45. Epub 2010 May 25.

PMID:
18382137
7.

Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.

Johnson RW.

Aging Clin Exp Res. 2009 Jun;21(3):236-43. Review.

PMID:
19571648
8.

Vaccination against Herpes Zoster and Postherpetic Neuralgia.

Oxman MN, Levin MJ; Shingles Prevention Study Group.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S228-36. doi: 10.1086/522159.

9.

Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.

Doan HQ, Ung B, Ramirez-Fort MK, Khan F, Tyring SK.

Expert Opin Biol Ther. 2013 Oct;13(10):1467-77. doi: 10.1517/14712598.2013.830101. Epub 2013 Aug 29.

PMID:
23984934
10.

[Herpes Zoster and its prevention in Italy. Scientific consensus statement].

Franco E, Gabutti G, Bonanni P, Conversano M, Stefano Valente ME, Ferro A, Icardi G, Antonio Volpi ML, Maggi S, Rossi A, Scotti S, Vitale F, Greco D; Italian Universities and Epidemiology.

Ig Sanita Pubbl. 2014 Jan-Feb;70(1):111-27. Italian.

PMID:
24770367
11.

Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.

Graham J, Mauskopf J, Kawai K, Johnson KD, Xu R, Acosta CJ.

J Manag Care Spec Pharm. 2016 Jul;22(7):872-88. doi: 10.18553/jmcp.2016.22.7.872.

12.

Vaccination: a new option to reduce the burden of herpes zoster.

Mick G.

Expert Rev Vaccines. 2010 Mar;9(3 Suppl):31-5. doi: 10.1586/erv.10.32. Review.

PMID:
20192716
13.

Community and patient values for preventing herpes zoster.

Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA.

Pharmacoeconomics. 2008;26(3):235-49.

PMID:
18282017
14.

A systematic review of the cost effectiveness of herpes zoster vaccination.

Szucs TD, Pfeil AM.

Pharmacoeconomics. 2013 Feb;31(2):125-36. doi: 10.1007/s40273-012-0020-7. Review.

PMID:
23335045
15.

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.

de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ.

Vaccine. 2013 Feb 18;31(9):1276-83. doi: 10.1016/j.vaccine.2012.12.067. Epub 2013 Jan 8.

PMID:
23306360
16.

Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.

Marin M, Yawn BP, Hales CM, Wollan PC, Bialek SR, Zhang J, Kurland MJ, Harpaz R.

Hum Vaccin Immunother. 2015;11(5):1157-64. doi: 10.1080/21645515.2015.1016681.

17.

Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older.

Izurieta HS, Wernecke M, Kelman J, Wong S, Forshee R, Pratt D, Lu Y, Sun Q, Jankosky C, Krause P, Worrall C, MaCurdy T, Harpaz R.

Clin Infect Dis. 2017 Mar 15;64(6):785-793. doi: 10.1093/cid/ciw854.

PMID:
28362955
18.

Cost effectiveness of herpes zoster vaccine in Canada.

Najafzadeh M, Marra CA, Galanis E, Patrick DM.

Pharmacoeconomics. 2009;27(12):991-1004. doi: 10.2165/11314010-000000000-00000.

PMID:
19908924
19.

Herpes zoster: diagnostic, therapeutic, and preventive approaches.

Bader MS.

Postgrad Med. 2013 Sep;125(5):78-91. doi: 10.3810/pgm.2013.09.2703. Review.

PMID:
24113666
20.

National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine.

Hurley LP, Harpaz R, Daley MF, Crane LA, Beaty BL, Barrow J, Babbel C, Marin M, Steiner JF, Davidson A, Dickinson LM, Kempe A.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S216-23. doi: 10.1086/522153.

PMID:
18419400

Supplemental Content

Support Center